Zealand Pharma
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Zealand Pharma sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Zealand Pharma: 18 sponsored US clinical trials, 1 recruiting.
Zealand Pharma sponsors 18 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 12 completed. 11 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Short Bowel Syndrome, with 4 trials.
Top-decile sponsor footprint
Zealand Pharma ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
18 total, page 1 of 1
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
NCT07197944
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
NCT06926842
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
NCT04881825
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
NCT03905707
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
NCT03941236
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
NCT06662539
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
NCT05378672
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
NCT04172441
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
NCT03777176
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
NCT03688711
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
NCT03690206
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
NCT03667053
A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
NCT03378635
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
NCT03279302
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
NCT03216226
Feasibility Trial Testing the Bionic Pancreas With ZP4207
NCT02971228
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose
NCT00868660
ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure
NCT00283361
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
| Phase 3 | 11 |
Therapeutic Areas
Where Zealand Pharma enrollment is open (later-stage tilt)
1 recruiting of 18 indexed (6% open); 12 completed (67%).
Phase mix: 11 late (III/IV) vs 7 early (I/II) (later-stage heavy).
Top condition: Short Bowel Syndrome (4 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Zealand Pharma: open-pipeline peers nationwide
Peers matched on 18 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Zealand Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 trials (± recruiting share)
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Boston College · 6% recruiting · 18 trials
- CytoDyn · 6% recruiting · 18 trials
- Dendreon · 6% recruiting · 18 trials
- Intercept Pharmaceuticals · 6% recruiting · 18 trials
Related
What to do with this Zealand Pharma page
18 registered trials is a research-attention snapshot, not an endorsement of Zealand Pharma or any single study.
- 1 of Zealand Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Short Bowel Syndrome is the condition Zealand Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Short Bowel Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Zealand Pharma pipeline card: 18 registered trials from official public datasets.Report a data error.